About this trial
To validate the accuracy of 68Ga-Pentixafor PET/CT and adrenal venous sampling (AVS) in subtype diagnosis of PA/ACS patients with adrenal nodules, based on biochemical and clinical remission outcomes, and to determine whether the diagnostic accuracy of 68Ga-Pentixafor PET/CT is non-inferior to AVS.
Eligibility criteria
Qualifiers
Getting the written informed consent;
PA conccurent with autonomous cortisol secretion;
Patients with hypertension aged 18-70 years;
CT or MRI scan of the adrenal glands with adenoma.
Disqualifiers
Unable to complete 68Ga-Pentixafor PET/CT or AVS;
Refusal of surgery or contraindications for surgery;
PA patients who meet the by-passing AVS criteria [i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone >300pg/ml]
Suspicion of familial hyperaldosteronism or Liddle syndrome. [i.e., age <20 years, hypertension and hypokalemia, or with family history];
Trial design
Treatments tested in this trial
- 68Ga-Pentixafor PET/CT
- AVS
Treatment groups
Sponsors and collaborators
Qifu Li
Lead sponsor
Chongqing Medical University
Sponsor institution
The Affiliated Hospital Of Southwest Medical University
Collaborator
Changzhi Medical College
Collaborator
First Affiliated Hospital of Kunming Medical University
Collaborator